AR126733A1 - Inhibidores de nicotinamida ripk1 - Google Patents
Inhibidores de nicotinamida ripk1Info
- Publication number
- AR126733A1 AR126733A1 ARP220102125A ARP220102125A AR126733A1 AR 126733 A1 AR126733 A1 AR 126733A1 AR P220102125 A ARP220102125 A AR P220102125A AR P220102125 A ARP220102125 A AR P220102125A AR 126733 A1 AR126733 A1 AR 126733A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- hydrogen
- group
- Prior art date
Links
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 title abstract 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 2
- 229960003966 nicotinamide Drugs 0.000 title 1
- 235000005152 nicotinamide Nutrition 0.000 title 1
- 239000011570 nicotinamide Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 101000854060 Homo sapiens Oxygen-regulated protein 1 Proteins 0.000 abstract 3
- 102100035714 Oxygen-regulated protein 1 Human genes 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 101000720693 Homo sapiens Oxysterol-binding protein-related protein 1 Proteins 0.000 abstract 1
- 101100224522 Mus musculus Dppa3 gene Proteins 0.000 abstract 1
- 101100329418 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRG1 gene Proteins 0.000 abstract 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
Abstract
En el presente documento se proporcionan compuestos de la fórmula (1) y sales aceptables desde el punto de vista farmacéutico de estos, útiles como inhibidores de RIPK1, y composiciones farmacéuticas que los comprenden. Además se proporcionan métodos de uso y preparación. Reivindicación 1: Un compuesto de la fórmula (1) o una sal aceptable desde el punto de vista farmacéutico de estos; en donde: R¹ es hidrógeno, o R¹ es -P(=O)(ORP¹)₂, -C(=O)CH₂ORP¹, -C(=O)CH₂N(RP¹)₂ o -C(=O)RP², en donde cada instancia de RP¹ se selecciona independientemente del grupo que consiste en hidrógeno y alquilo C₁₋₄ sustituido o no sustituido, y RP² es alquilo C₁₋₄ sustituido o no sustituido; R²A y R²B son cada uno independientemente hidrógeno o halo; cada R³ se selecciona independientemente del grupo que consiste en halo y alquilo C₁₋₄ sustituido o no sustituido, en donde n es 0, 1 o 2; RN¹ es hidrógeno o alquilo C₁₋₄ sustituido o no sustituido; R⁴ se selecciona independientemente del grupo que consiste en hidrógeno, -OR⁴A y alquilo C₁₋₄ sustituido o no sustituido, en donde R⁴A es hidrógeno o alquilo C₁₋₄ sustituido o no sustituido; R⁵ se selecciona independientemente del grupo que consiste en hidrógeno, -OR⁵A y alquilo C₁₋₄ sustituido o no sustituido, en donde R⁵A es hidrógeno o alquilo C₁₋₄ sustituido o no sustituido; El anillo G es un anillo heteroarilo de 5 miembros, en donde cada G¹, G², G³ y G⁴ es, independientemente, CH, CRG¹, N, NRN², O o S, siempre que al menos uno de G¹, G², G³ y G⁴ sea N, NRN², O o S, y en donde no más de dos de G¹, G², G³ y G⁴ son O o S; cada instancia de RG¹ se selecciona independientemente del grupo que consiste en halo, -ORG², -NR⁷, alquilo C₁₋₄ sustituido o no sustituido, carbociclilo de 3 a 4 miembros sustituido o no sustituido, o heterociclilo de 4 miembros sustituido o no sustituido, en donde RG² es hidrógeno o alquilo C₁₋₄ sustituido o no sustituido; o dos grupos RG¹ vecinales, tomados junto con los átomos a los que están unidos, forman un carbociclilo fusionado de 5 - 6 miembros sustituido o no sustituido o un heterociclilo fusionado de 5 - 6 miembros sustituido o no sustituido; o un grupo RG¹ vecinal y un grupo RN², tomados junto con los átomos a los que están unidos, forman un heterociclilo fusionado de 5 - 6 miembros sustituido o no sustituido; cada RN² se selecciona independientemente del grupo que consiste en hidrógeno, alquilo C₁₋₄ sustituido o no sustituido, carbociclilo de 3 - 4 miembros sustituido o no sustituido y heterociclilo de 4 miembros sustituido o no sustituido; cada R⁷ se selecciona independientemente del grupo que consiste en hidrógeno, alquilo C₁₋₄ sustituido o no sustituido, carbociclilo de 3 - 4 miembros sustituido o no sustituido y heterociclilo de 4 miembros sustituido o no sustituido; y cada instancia de sustituido o no sustituido está opcional e independientemente sustituido por 0, 1, 2 o 3 sustituyentes seleccionados del grupo que consiste en halo, -OH, - O(alquilo C₁₋₄) y -O(haloalquilo C₁₋₄).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231590P | 2021-08-10 | 2021-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126733A1 true AR126733A1 (es) | 2023-11-08 |
Family
ID=83439074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102125A AR126733A1 (es) | 2021-08-10 | 2022-08-08 | Inhibidores de nicotinamida ripk1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11767310B2 (es) |
| EP (1) | EP4301744A1 (es) |
| JP (2) | JP7406672B2 (es) |
| KR (2) | KR20240135076A (es) |
| CN (1) | CN117460722A (es) |
| AR (1) | AR126733A1 (es) |
| AU (1) | AU2022328136A1 (es) |
| BR (1) | BR112023025850A2 (es) |
| CA (1) | CA3219155A1 (es) |
| CO (1) | CO2023017151A2 (es) |
| IL (1) | IL308349A (es) |
| MX (1) | MX2023014817A (es) |
| TW (1) | TW202321211A (es) |
| WO (1) | WO2023018643A1 (es) |
| ZA (1) | ZA202310682B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR126733A1 (es) | 2021-08-10 | 2023-11-08 | Abbvie Inc | Inhibidores de nicotinamida ripk1 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997005131A1 (en) | 1995-08-02 | 1997-02-13 | J. Uriach & Cia. S.A. | New carboxamides with antifungal activity |
| US6723727B1 (en) | 1996-12-20 | 2004-04-20 | Hoechst Aktiengesellschaft | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them |
| US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
| PL1664026T3 (pl) | 2003-08-15 | 2009-06-30 | Merck Sharp & Dohme | Inhibitory kinezyny mitotycznej |
| CN1835756A (zh) | 2003-08-15 | 2006-09-20 | 默克公司 | 有丝分裂驱动蛋白抑制剂 |
| US7112316B1 (en) | 2005-08-08 | 2006-09-26 | Uop Llc | Process for preparing molecular sieves via continuous addition of nutrients |
| US20100121048A1 (en) | 2006-02-16 | 2010-05-13 | Takanobu Kuroita | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension |
| ATE505454T1 (de) | 2007-09-20 | 2011-04-15 | Amgen Inc | 1-(4-(4-benzylbenzamid)-benzyl)-azetidin-3- carboxylsäurederivate und entsprechende verbindungen als s1p-rezeptor-modulatoren zur behandlung von immunerkrankungen |
| JP5557832B2 (ja) | 2008-03-18 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 置換４−ヒドロキシピリジン−５−カルボキサミド |
| RU2541571C2 (ru) | 2009-04-15 | 2015-02-20 | Эббви Инк. | Противовирусные соединения |
| WO2011113707A1 (en) | 2010-03-17 | 2011-09-22 | Exxonmobil Chemical Patents Inc. | Plasticiser blends and compositions and articles made therefrom |
| WO2012052167A1 (en) | 2010-10-20 | 2012-04-26 | Grünenthal GmbH | Substituted 6-amino-nicotinamides as kcnq2/3 modulators |
| WO2013049255A1 (en) | 2011-09-26 | 2013-04-04 | Vanderbilt University | Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| WO2015100322A1 (en) | 2013-12-24 | 2015-07-02 | Oncotartis, Inc. | Benzamide and nicotinamide compounds and methods of using same |
| KR101551313B1 (ko) | 2014-07-28 | 2015-09-09 | 충남대학교산학협력단 | 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물 |
| KR101555033B1 (ko) | 2014-07-28 | 2015-09-23 | 충남대학교산학협력단 | 신규한 메타논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물 |
| AU2015304851A1 (en) | 2014-08-21 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as RIP1 kinase inhibitors as medicaments |
| EP3224237B1 (en) | 2014-12-24 | 2024-09-11 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| MX2017016482A (es) | 2015-07-02 | 2018-03-08 | Hoffmann La Roche | Lactamas biciclicas y metodos de uso de las mismas. |
| CN108431004B (zh) | 2015-10-23 | 2021-02-12 | 武田药品工业株式会社 | 杂环化合物 |
| WO2017096301A1 (en) | 2015-12-04 | 2017-06-08 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1) |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| JP6974331B2 (ja) | 2016-02-05 | 2021-12-01 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 化合物、組成物及び方法 |
| JP7121731B2 (ja) | 2016-09-26 | 2022-08-18 | タフツ・ユニバーシティ | ウリジンヌクレオシド誘導体、組成物及び使用方法 |
| RS62801B1 (sr) | 2017-02-13 | 2022-02-28 | Bristol Myers Squibb Co | Aminotriazolopiridini kao inhibitori kinaze |
| DE102017211104B3 (de) | 2017-06-29 | 2018-10-18 | Bundesdruckerei Gmbh | Verfahren und Vorrichtung zum Verifizieren eines elektrolumineszierenden Sicherheitsmerkmals in einem Wert- oder Sicherheitsdokument unter Ausnutzung von zusätzlicher Lichtstrahlung |
| JP2021523226A (ja) | 2018-05-03 | 2021-09-02 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法 |
| US11840535B2 (en) | 2018-07-02 | 2023-12-12 | Shenzhen Targetrx, Inc. | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity |
| KR20200006495A (ko) | 2018-07-10 | 2020-01-20 | 보로노이바이오 주식회사 | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
| WO2020149553A1 (ko) * | 2019-01-15 | 2020-07-23 | 주식회사 보로노이 | 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
| AR126733A1 (es) | 2021-08-10 | 2023-11-08 | Abbvie Inc | Inhibidores de nicotinamida ripk1 |
-
2022
- 2022-08-08 AR ARP220102125A patent/AR126733A1/es unknown
- 2022-08-08 US US17/882,709 patent/US11767310B2/en active Active
- 2022-08-08 JP JP2023516136A patent/JP7406672B2/ja active Active
- 2022-08-08 IL IL308349A patent/IL308349A/en unknown
- 2022-08-08 KR KR1020247029687A patent/KR20240135076A/ko unknown
- 2022-08-08 EP EP22777032.8A patent/EP4301744A1/en active Pending
- 2022-08-08 WO PCT/US2022/039689 patent/WO2023018643A1/en active Application Filing
- 2022-08-08 TW TW111129732A patent/TW202321211A/zh unknown
- 2022-08-08 MX MX2023014817A patent/MX2023014817A/es unknown
- 2022-08-08 AU AU2022328136A patent/AU2022328136A1/en active Pending
- 2022-08-08 KR KR1020237038931A patent/KR102707109B1/ko active IP Right Grant
- 2022-08-08 CN CN202280041334.6A patent/CN117460722A/zh active Pending
- 2022-08-08 CA CA3219155A patent/CA3219155A1/en active Pending
- 2022-08-08 BR BR112023025850A patent/BR112023025850A2/pt unknown
-
2023
- 2023-11-17 ZA ZA2023/10682A patent/ZA202310682B/en unknown
- 2023-12-11 CO CONC2023/0017151A patent/CO2023017151A2/es unknown
- 2023-12-14 JP JP2023210859A patent/JP2024037892A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023025850A2 (pt) | 2024-03-05 |
| JP2023549007A (ja) | 2023-11-22 |
| MX2023014817A (es) | 2024-01-12 |
| KR20230163568A (ko) | 2023-11-30 |
| CN117460722A (zh) | 2024-01-26 |
| WO2023018643A1 (en) | 2023-02-16 |
| CA3219155A1 (en) | 2023-02-16 |
| AU2022328136A1 (en) | 2023-11-30 |
| KR102707109B1 (ko) | 2024-09-20 |
| IL308349A (en) | 2024-01-01 |
| ZA202310682B (en) | 2024-08-28 |
| KR20240135076A (ko) | 2024-09-10 |
| CO2023017151A2 (es) | 2023-12-29 |
| JP7406672B2 (ja) | 2023-12-27 |
| JP2024037892A (ja) | 2024-03-19 |
| EP4301744A1 (en) | 2024-01-10 |
| US20230127127A1 (en) | 2023-04-27 |
| US11767310B2 (en) | 2023-09-26 |
| TW202321211A (zh) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114254A1 (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores | |
| AR109349A1 (es) | Compuestos y usos | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| AR117617A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1 | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR090191A1 (es) | Derivados del acido fenil alcanoico como agonistas gpr | |
| AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
| AR055041A1 (es) | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR094790A1 (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| AR116464A1 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| AR126733A1 (es) | Inhibidores de nicotinamida ripk1 | |
| AR116400A1 (es) | Compuesto de imidazopiridinona | |
| AR123962A1 (es) | Inhibidores de interleucina-17 | |
| PE20212327A1 (es) | Ciertos compuestos de pladienolida y metodos de uso | |
| AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh | |
| AR119140A1 (es) | Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco | |
| AR118641A1 (es) | Compuestos, composiciones y métodos | |
| AR046617A1 (es) | Compuestos inhibidores de selectina | |
| AR125365A1 (es) | Derivados de 1h-pirazol como ligandos sigma | |
| AR100126A1 (es) | Activadores de herg policíclicos | |
| AR121554A1 (es) | Azálidos de urea inmunoduladores |